急性非淋巴细胞白血病的治疗
Treatment of Acute Non-Lymphocytic Leukemia
出处
《内科急危重症杂志》
2005年第3期99-101,118,共4页
Journal of Critical Care In Internal Medicine
参考文献14
-
1Richard M Stone,Margaret R O’Donnell,and Mikkael A.Sekeres.Acute Myeloid Leukemia.Heamatology,2004:98.
-
2Stone RM. Treatment of acute myeloid leukemia:state-of-the-art and future directions. Semin Hematol,2002,39(3 Supp1 2): 4.
-
3Tavernier E, Le QH, Elhamri M, et al. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors. Leuk Res,2003,27:205.
-
4Slovak M, Kopecky K, Cassileth P, et al. Karyotypic analysis predicts outcome of Preremission and post remisssion therapy in adults acute myeloid leukemia: A SWOG/ECOG study. Blood,2000,96:4075.
-
5Jackson GH. Use of fludarabine in the treatment of acute myeloid leukemia. Hematol J. 2004,5 Suppl 1:S62.
-
6Kantarjian H, Gandhi V, Cortes .L Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood,2003,102: 2379.
-
7Tang R, Faussat AM, Majdak P,er al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRPI : Leukemia,2004,18:1246.
-
8Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood,2004.103,3669.
-
9Giles FJ, Stopeck AT, Silverman LR,et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood,2003,102: 795.
-
10Cortes J, Giles F, Obfien S, et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer, 2003,97:2760.
-
1盛德平.输血后肝炎对急性非淋巴细胞白血病预后的影响[J].临床医学,1996,16(3):27-28.
-
2王欢,胡荣,刘卓刚.沙利度胺联合三氧化二砷对急性非淋巴细胞白血病细胞血管内皮生长因子表达的影响(英文)[J].中国现代医学杂志,2007,17(12):1418-1420. 被引量：2
-
3叶欣,李秀兰,黎爱华,周丽,孙兆刚,滕清良,李栋.应用前列腺素E_1预防和治疗急性非淋巴细胞白血病联合化疗时所并发的弥散性血管内凝血[J].中华血液学杂志,1998,19(10):552-553. 被引量：2
-
4李战强,杨平地,兰雨,沈建良,向丹.白塞病合并骨髓增生异常综合征1例并文献回顾[J].转化医学杂志,2000(4):254-255. 被引量：1
-
5庞伟君,张宇明.AML患者治疗前后LDH、IL-2、IL-12水平的变化及临床意义[J].实用医技杂志,2005,12(11A):3044-3045.
-
6岳兰竹,付蓉,阮二宝,瞿文,梁勇,王国锦,王晓明,刘鸿,宋嘉,关晶,吴玉红,王化泉,邢莉民,李丽娟,王珺,邵宗鸿.急性非淋巴细胞白血病化疗肝损伤发生率及其相关因素研究[J].中国实用内科杂志,2009,29(11):1009-1011. 被引量：4
-
7徐淑芬,欧英贤,白海,王存邦,路继红,陆井之.再生障碍性贫血患者细胞遗传学异常的相关因素分析[J].中国综合临床,2005,21(4):298-300.
-
8陈育红.“去甲基化”时代论异基因造血干细胞移植治疗骨髓增生异常综合征的进展[J].国际输血及血液学杂志,2013,36(4):388-391. 被引量：2
-
9孙博楠.HA-C方案治疗急性非淋巴细胞白血病206例临床观察[J].中国现代药物应用,2009,3(13):56-56.
-
10唐志坚（摘）.NCCN修订癌症治疗指南[J].国外药讯,2008(3):2-3.
